Chronic Obstructive Pulmonary
Conditions
Keywords
COPD (Chronic Obstructive Pulmonary Patients), Atrophy, cell cultur, systemic inflammation, Catabolism
Brief summary
Chronic Obstructive Pulmonary Patients is a defined by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. It is associated with an atrophy of the skeletal muscle that impairs the patient's prognosis. The biological mechanisms of this muscle atrophy have not been elucidated, and the spill-over theory has recently emerged. Indeed, in COPD patients, the pulmonary inflammation is associated with a systemic low-grade inflammation, and the increased pro-inflamatory molelcules in the blood - which constitute the cellular micro-environement of the muscle fibre - could activate the mechanisms of the cell atrophy.
Interventions
OTHERDetermination of pro-inflammatory plasma factors
Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old
Sponsors
University Hospital, Montpellier
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
35 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
35 to 85 years old * COPD patients: association of symtoms (breathlessness, cough, sputum) and chronic exposure to inhalated risk factors (like tobacco smoke) and a FEV1/VC ratio \<70% assessed by a spirometry * Healthy subjects: A sedentariness assessed by a Voorrips score \<9.4 and/or a report of \<150 min/week of moderate-to-vigorous physical activity
Exclusion criteria
* A recent COPD exacerbation (\< 4weeks) * The decompensation of a comorbidity * An antioxidant supplementation or medication * A long-term systemic corticosteroid medication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Myotube diameter of in vitro cultured myotubes | 6 days | Myotube diameter of in vitro cultured myotubes from healthy subjects, exposed to the serum of healthy controls and COPD patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Expression and translation of markers of | 6 days | Expression and translation of markers of anabolic and catabolic pathways |
Other
| Measure | Time frame | Description |
|---|---|---|
| Level of pro-Inflamatory markers | 6 days | Level of pro-Inflamatory markers in the serum |
Countries
France
Outcome results
None listed